Rationally designed heparinases derived from heparinase I...

Details Rationally designed heparinases derived from heparinase I... Rationally designed heparinases derived from heparinase I...

2006-06-06

2006-06-06

Hutson, Richard (Department: 1652)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Transferases

C435S002000, C435S232000, C435S252330, C435S320100, C536S023200

Reexamination Certificate

active

07056504

ABSTRACT:
Modified heparinases having altered binding specificity and activity are provided. Isolated nucleic acids encoding the same as well as vectors and host cells are provided. Methods for using the modified heparinases are also provided.

REFERENCES:
patent: 4281108 (1981-07-01), Fussi
patent: 4341869 (1982-07-01), Langer, Jr. et al.
patent: 4373023 (1983-02-01), Langer et al.
patent: 4396762 (1983-08-01), Langer et al.
patent: 4443545 (1984-04-01), Langer, Jr. et al.
patent: 4551296 (1985-11-01), Kavesh et al.
patent: 4679555 (1987-07-01), Sackner
patent: 4745105 (1988-05-01), Griffin et al.
patent: 4757056 (1988-07-01), Van Gorp et al.
patent: 4830013 (1989-05-01), Maxwell
patent: 4928694 (1990-05-01), Maxwell
patent: 4942156 (1990-07-01), Foley et al.
patent: 4990502 (1991-02-01), Lormeau et al.
patent: 5010063 (1991-04-01), Piani et al.
patent: 5039529 (1991-08-01), Bergendal et al.
patent: 5106734 (1992-04-01), Nielsen
patent: 5152784 (1992-10-01), Tsilibary
patent: 5164378 (1992-11-01), Conti et al.
patent: 5169772 (1992-12-01), Zimmerman et al.
patent: 5204323 (1993-04-01), Findlay et al.
patent: 5252339 (1993-10-01), Cristofori et al.
patent: 5262325 (1993-11-01), Zimmermann et al.
patent: 5290695 (1994-03-01), Morikawa et al.
patent: 5338677 (1994-08-01), Zimmermann et al.
patent: 5389539 (1995-02-01), Sasisekharan et al.
patent: 5453171 (1995-09-01), Ma et al.
patent: 5474987 (1995-12-01), Cohen et al.
patent: 5567417 (1996-10-01), Sasisekharan et al.
patent: 5569366 (1996-10-01), Chen et al.
patent: 5569600 (1996-10-01), Sasisekharan et al.
patent: 5576304 (1996-11-01), Kakkar et al.
patent: 5599801 (1997-02-01), Branellec et al.
patent: 5607859 (1997-03-01), Biemann et al.
patent: 5618917 (1997-04-01), Toback et al.
patent: 5619421 (1997-04-01), Venkataraman et al.
patent: 5681733 (1997-10-01), Su et al.
patent: 5687090 (1997-11-01), Chen et al.
patent: 5714376 (1998-02-01), Sasisekharan et al.
patent: 5744515 (1998-04-01), Clapper
patent: 5752019 (1998-05-01), Rigoutsos et al.
patent: 5753445 (1998-05-01), Fillit et al.
patent: 5759767 (1998-06-01), Lakowicz et al.
patent: 5763427 (1998-06-01), Weitz et al.
patent: 5767269 (1998-06-01), Hirsh et al.
patent: 5776434 (1998-07-01), Purewal et al.
patent: 5795875 (1998-08-01), Holme et al.
patent: 5808021 (1998-09-01), Holme et al.
patent: 5824299 (1998-10-01), Luster et al.
patent: 5830726 (1998-11-01), Sasisekharan et al.
patent: 5855913 (1999-01-01), Hanes et al.
patent: 5856928 (1999-01-01), Yan
patent: 5874064 (1999-02-01), Edwards et al.
patent: 5879713 (1999-03-01), Roth et al.
patent: 5919693 (1999-07-01), Su et al.
patent: 5922358 (1999-07-01), Doutremepuich et al.
patent: 5952653 (1999-09-01), Covey et al.
patent: 5968822 (1999-10-01), Pecker et al.
patent: 5985309 (1999-11-01), Edwards et al.
patent: 5990097 (1999-11-01), Kennedy
patent: 5993846 (1999-11-01), Friedman et al.
patent: 5997863 (1999-12-01), Zimmermann et al.
patent: 6013628 (2000-01-01), Skubitz et al.
patent: 6116237 (2000-09-01), Schultz et al.
patent: 6136295 (2000-10-01), Edwards et al.
patent: RE37053 (2001-02-01), Hanes et al.
patent: 6190875 (2001-02-01), Ben-Artzi et al.
patent: 6217863 (2001-04-01), Godavarti et al.
patent: 6268146 (2001-07-01), Shultz et al.
patent: 6291439 (2001-09-01), Klock
patent: 6309853 (2001-10-01), Friedman et al.
patent: 6333051 (2001-12-01), Kabanov et al.
patent: 6597996 (2003-07-01), Venkataraman et al.
patent: 0 140 781 (1985-05-01), None
patent: 0 114 589 (1987-09-01), None
patent: 0 244 236 (1987-11-01), None
patent: 0 394 971 (1990-10-01), None
patent: 0 433 225 (1990-11-01), None
patent: 0 557 887 (1993-02-01), None
patent: 0 342 215 (1993-08-01), None
patent: WO 92/01003 (1992-01-01), None
patent: WO 93/05167 (1993-03-01), None
patent: WO93/08289 (1993-04-01), None
patent: WO 93/10450 (1993-05-01), None
patent: WO 93/15406 (1993-08-01), None
patent: WO 93/19096 (1993-09-01), None
patent: WO 93/19734 (1993-10-01), None
patent: WO 94/12618 (1994-06-01), None
patent: WO 94/21689 (1994-09-01), None
patent: WO 95/13830 (1995-05-01), None
patent: WO 95 34635 (1995-12-01), None
patent: WO 96/01648 (1996-01-01), None
patent: PCT/US96/17310 (1996-10-01), None
patent: WO 96/32149 (1996-10-01), None
patent: WO 97/06783 (1997-02-01), None
patent: WO 97/11684 (1997-04-01), None
patent: WO 97/16556 (1997-05-01), None
patent: WO 97/35562 (1997-10-01), None
patent: WO 98/04902 (1998-02-01), None
patent: WO 98/31346 (1998-07-01), None
patent: WO 00/12726 (2000-03-01), None
patent: PCT US99 19841 (2000-04-01), None
patent: WO 00/65521 (2000-11-01), None
Shriver, Z.. et al., “Heparinase II from flavobacterium hepainum: Role of histidine residues in enzymatic activity as probed by chemical modification and site-directed mutagenesis,”Journal of Biological Chemistry, vol. 273, No. 36, 1998, pp. 10160-10167.
Shriver, Z.. et al., “Heparinase II from flavobacterium hepainum: Role of cysteine in enzymatic activity as probed by chemical modification and site-directed mutagenesis,”Journal of Biological Chemistry, vol. 273, No. 17, 1998, pp. 22904-22912.
Ameer et al., “A New Approach to Regional Heparinization: Design and Development of a Novel Immobilized Heparinase Device”,Blood Purification Meeting Information: The International Conference on Continuous Renal Replacement Therapies, 16(2): 107-118, 1998. Abstract Only.
Berry et al., “Distinct Heparan Sulfate Glycosaminoglycans are Responsible for Mediating Fibroblast Growth Factor-2 Biological Activity Through Different Fibroblast Growth Factor Receptors”,The FASEB Journal Online, Article #: 10.1096/fj.00-0661fje: 1-19, 2001.
Biemann, “Four Decades of Structure Determination by Mass Spectrometry: From Alkaloids to Heparin”,J. Am. Soc. Mass. Spectrom., 13: 1254-1272, 2002.
Carlson et al., “Behavior of Antithrombin III Isoforms on Immobilized Heparins: Evidence that the Isoforms Bind to Different Numbers of Low-affinity Heparin Sites”,The Journal of Biological Chemistry, 263(5): 2187-2194, 1988.
Claverie et al., “Information Enhancement Methods for Large Scale Sequence Analysis”,Computers Chem., 17(2): 191-201, 1993.
Crum et al., “A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment”,Science, 230: 1375-1378, 1985.
Dull et al., “Lung Endothelial Heparan Sulfates Mediate Cationic Peptide-induced Barrier Dysfunction: A New Role for the Glycocalyx”,Am. J. Physiol. Lung Cell Mol. Physiol., 285: L986-995, 2003.
Edwards et al., “Large Porous Particles for Pulmonary Drug Delivery”,Science Reprint Series, 276: 1868-1871, 1997.
Edwards et al., “Recent Advances in Pulmonary Drug Delivery Using Large, Porous Inhaled Particles”,J. Appl. Physiol., 85(2): 379-385 , 1998.
Ernst et al., “Expression inEscherichia coli, Purification and Characterization of Heparinase I fromFlavobacterium heparinum”, Biochem. J., 315: 589-597, 1996.
Ernst et al., “Enzymatic Degradation of Glycosaminoglycans”,Critical Reviews in Biochemistry and Molecular Biology, 30(5): 387-444, 1995.
Ernst et al., “Direct Evidence for a Predominantly Exolytic Processive Mechanism for Depolymerization of Heparin-like Glycosaminoglycans by Heparinase I”,Proc. Natl. Acad. Sci. USA, 95: 4182-4187, 1998.
Folkman et al., “Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone”,Science, 221:719-725, 1983.
Gioldassi et al., “Determination of Phosphorylated and Sulfated Linkage-region Oligosaccharides in Chondroitin / Dermatan and Heparan Sulfate Proteoglycans by High Performance Liquid Chromatography”,J. Liq. Chrom.&Rel. Technol., 22(13): 1997-2007, 1999.
Godavarti et al., “Heparinase III fromFlavobacterium heparinum: Cloning and Recombinant Expression inEscherichia coli”, Biochemical and Biophysical Research Communications, 225(3): 751-758, 1996.
Godavarti et al., “A Comparative Analysis of the P

Affiliated with

Also associated with

Rating

Rationally designed heparinases derived from heparinase I... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Rationally designed heparinases derived from heparinase I..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rationally designed heparinases derived from heparinase I... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3660200